Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (1112)	6/17/1998 2:04:00 AM
From: Stephen How	Read Replies (1) \| Respond to of 4634

The Wall Street Journal ran an article on short traders and in it Asensio took his swings at BTIM again but apparently the WSJ writer felt journalistic fairness should include this disclosure. Jim, Are you referring to the WSJ article featuring the dubious value of Biotime? BioTime's Shares Feel the Burden Of Proof for Developing Product (https://www.siliconinvestor.com/readmsg.aspx?msgid=4280851): "Manuel Asensio, president of Asensio & Co. in New York, ... has a short position in BioTime of more than 200,000 shares." I don't know if you mean that article, because it really focused on the scientific basis for evaluating Biotime's lead product Hextend&reg. Asensio was only mentioned in 2 sentenances of the article. The article featured a blood expert at the University of California at San Diego, who was skeptical of the competativeness of the product. This may have been the only WSJ article mentioning the size of Asensio's short position on BTIM. I understand how you are concerned with the misrepresentation of facts out there. Steve My BTIM site on my server: btim.dyn.ml.org